Tarsons Products Limited has informed the Exchange about General Updates
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tarsons Products Limited has completed the first tranche of an equity infusion into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., investing EUR 300,000 by subscribing to 100 equity shares at a nominal value of EUR 3,000 per share. This is part of a larger plan announced on February 6, 2026, to invest a total of EUR 3 million (three million euros) in the subsidiary, with further tranches to follow. The funds will be used to repay a bank loan taken in Singapore on a quarterly basis, pay interest on that loan, and cover general corporate and operational expenses. The subsidiary is a Special Purpose Vehicle incorporated in November 2023 with nil turnover since inception, and ownership remains 100% with Tarsons Products Limited.
The investment is a routine internal capital infusion into an existing wholly-owned subsidiary, with no change in ownership or consolidation impact. The use of proceeds to service Singapore bank debt suggests the subsidiary has ongoing loan obligations, but the small size of this first tranche (EUR 300K out of a planned EUR 3M) makes it neutral for shareholders in the near term.